Diabetes mellitus (DM) is a global health problem for millions of people worldwide. Nowadays, medicinal plants have started gaining more attention to diabetes management due to minimal side effects and cost-effectiveness. This study aims to ascertain the antidiabetic potential of Etlingera elatior flowers aqueous extract (EEAE) on in vitro inhibition of carbohydrate digestive enzymes and in vivo type 2 DM rat model. Findings demonstrated that E. elatior flower has a high percentage of inhibitory activity against α-amylase (99.70 ± 2.88%) and moderate activity for the α-glucosidase enzyme (52.39 ± 1.50%). Besides, E. elatior flower also has exhibited an antihyperglycaemic effect that is dose-dependent and has significantly decreased the elevated total cholesterol, triglycerides, and LDL levels in the in vivo study. Furthermore, serum creatinine, AST, and ALP also have significantly decreased when compared to untreated DM. The high content of total phenolic (39.06 ± 1.59 mg GAE/g), total flavonoid (39.00 ± 2.42 mg GAE/g extract), and potent antioxidant activity was suggested to contribute in the antidiabetic activity of the extract. In conclusion, E. elatior flower potentially could be developed as a natural source of antioxidants that can be used for the prevention or treatment of diabetes.
Keywords: Etlingera elatior, antidiabetic activity, in vitro, in vivo.
Key words: Etlingera elatior, antidiabetic activity, in vitro, in vivo.
|
